Razelle Kurzrock

Also affiliated with Medical College of Wisconsin, Society for Immunotherapy of Cancer, UC San Diego Health System, Worldwide Universities Network, OW2 Consortium

Biochemistry, Genetics and Molecular BiologyMedicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 2%percentile

2.3Author DataRank

Indexed papers

10in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 10 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Real-World Data From a Molecular Tumor Board: Improved Outcomes in Breast and Gynecologic Cancers Patients With Precision Medicine

JCO Precision Oncology(2022)10.1200/po.20.00508

Top 22%

0.918DataRank

Top 22%17 citations

Ramez N. Eskander, Jason K. Sicklick, Ki Hwan Kim, Hyo Jeong Lim, Ryosuke Okamura +8 more

Papers

Driven by 123 papers — median percentile 53. Top paper: “Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART)”.

Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART)

Journal for ImmunoTherapy of Cancer(2021)10.1136/jitc-2021-002990

N/A

4.8DataRank · unranked

160 citations

Megan Othus, Sandip Pravin Patel, Chris Ryan, Ashish Sangal, Benjamin Powers +15 more

A Multicenter Phase II Trial of Ipilimumab and Nivolumab in Unresectable or Metastatic Metaplastic Breast Cancer: Cohort 36 of Dual Anti–CTLA-4 and Anti–PD-1 Blockade in Rare Tumors (DART, SWOG S1609)

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-21-2182

N/A

3.8DataRank · unranked

125 citations

Megan Othus, Sandip Pravin Patel, Kathy D. Miller, Rashmi Chugh, Scott M. Schuetze +23 more

MHC-I genotype and tumor mutational burden predict response to immunotherapy

Genome Medicine(2020)10.1186/s13073-020-00743-4

N/A

3.4DataRank · unranked

115 citations

Andrea Castro, Rachel Marty Pyke, Ryosuke Okamura, Shumei Kato, Paul Riviere +7 more

Atezolizumab Treatment of Tumors with High Tumor Mutational Burden from MyPathway, a Multicenter, Open-Label, Phase IIa Multiple Basket Study

Cancer Discovery(2021)10.1158/2159-8290.cd-21-0450

N/A

3.0DataRank · unranked

101 citations

John D. Hainsworth, Razelle Kurzrock, David R. Spigel, Howard A. Burris, Christopher J. Sweeney +9 more

SWI/SNF complex alterations as a biomarker of immunotherapy efficacy in pancreatic cancer

JCI Insight(2021)10.1172/jci.insight.150453

N/A

2.2DataRank · unranked

68 citations

Shumei Kato, Hitendra Patel, Paul T. Fanta, Suzanna Lee, Ryosuke Okamura +2 more

Outcome differences by sex in oncology clinical trials

Nature Communications(2024)10.1038/s41467-024-46945-x

N/A

2.2DataRank · unranked

60 citations

Alejandro A. Schäffer, Padma Sheila Rajagopal, Razelle Kurzrock, Eytan Ruppin, Ashwin V. Kammula

Molecular profiling of advanced malignancies guides first-line N-of-1 treatments in the I-PREDICT treatment-naïve study

Genome Medicine(2021)10.1186/s13073-021-00969-w

N/A

1.9DataRank · unranked

90 citations

Shumei Kato, Ryosuke Okamura, Hitendra Patel, Mina Nikanjam, Paul T. Fanta +14 more

Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-20-1215

N/A

1.3DataRank · unranked

41 citations

Haeseong Park, S. Greg Call, Kiran Madwani, Yasuhiro Oki, Vivek Subbiah +17 more

Targeting G1/S phase cell-cycle genomic alterations and accompanying co-alterations with individualized CDK4/6 inhibitor–based regimens

JCI Insight(2021)10.1172/jci.insight.142547

N/A

1.1DataRank · unranked

31 citations

Ryosuke Okamura, Jacob J. Adashek, Noor Khalid, Suzanna Lee, Van Thomas Nguyen +3 more

Review of precision cancer medicine: Evolution of the treatment paradigm

Cancer Treatment Reviews(2020)10.1016/j.ctrv.2020.102019

N/A

0.996DataRank · unranked

762 citations

Elena Fountzilas, Mina Nikanjam, Razelle Kurzrock, Apostolia M. Tsimberidou

Tumor mutational burden is not predictive of cytotoxic chemotherapy response

OncoImmunology(2020)10.1080/2162402x.2020.1781997

N/A

0.989DataRank · unranked

17 citations

Paul Riviere, Aaron M. Goodman, Donald A. Barkauskas, Garrett M. Frampton, Razelle Kurzrock +1 more

Real-World Data From a Molecular Tumor Board: Improved Outcomes in Breast and Gynecologic Cancers Patients With Precision Medicine

JCO Precision Oncology(2022)10.1200/po.20.00508

Top 22%

0.918DataRank

Top 22%17 citations

Ramez N. Eskander, Jason K. Sicklick, Ki Hwan Kim, Hyo Jeong Lim, Ryosuke Okamura +8 more

Real-world data from a molecular tumor board demonstrates improved outcomes with a precision N-of-One strategy

Nature Communications(2020)10.1038/s41467-020-18613-3

N/A

0.859DataRank · unranked

305 citations

Ki Hwan Kim, Hyo Jeong Lim, Amélie Boichard, Mina Nikanjam, Elizabeth Weihe +17 more

The FDA approval of pembrolizumab for adult and pediatric patients with tumor mutational burden (TMB) ≥10: a decision centered on empowering patients and their physicians

Annals of Oncology(2020)10.1016/j.annonc.2020.07.002

N/A

0.831DataRank · unranked

253 citations

David B. Solit, Timothy A. Chan, Razelle Kurzrock, Vivek Subbiah

Intra-patient stability of tumor mutational burden from tissue biopsies at different time points in advanced cancers

Genome Medicine(2021)10.1186/s13073-021-00979-8

N/A

0.801DataRank · unranked

14 citations

Aaron M. Goodman, Smruthy Sivakumar, Garrett M. Frampton, Razelle Kurzrock, Timothy V. Pham

ARID1A alterations function as a biomarker for longer progression-free survival after anti-PD-1/PD-L1 immunotherapy

Journal for ImmunoTherapy of Cancer(2020)10.1136/jitc-2019-000438

N/A

0.790DataRank · unranked

193 citations

Shumei Kato, Suzanna Lee, Rebecca E. Jimenez, Jason K. Sicklick, Razelle Kurzrock +1 more

Transcriptomics and solid tumors: The next frontier in precision cancer medicine

Seminars in Cancer Biology(2020)10.1016/j.semcancer.2020.09.007

N/A

0.704DataRank · unranked

108 citations

Elena Fountzilas, Leonidas Bleris, Razelle Kurzrock, Apostolia M. Tsimberidou

High Tumor Mutational Burden Correlates with Longer Survival in Immunotherapy-Naïve Patients with Diverse Cancers

Molecular Cancer Therapeutics(2020)10.1158/1535-7163.mct-20-0161

N/A

0.700DataRank · unranked

105 citations

Aaron M. Goodman, Ryosuke Okamura, Donald A. Barkauskas, Theresa J. Whitchurch, Suzanna Lee +9 more

Considering molecular alterations as pan-cancer tissue-agnostic targets

Nature Cancer(2023)10.1038/s43018-023-00676-y

N/A

0.693DataRank · unranked

11 citations

Shumei Kato, Jason K. Sicklick, Scott M. Lippman, Razelle Kurzrock, Jacob J. Adashek

T-cell priming transcriptomic markers: implications of immunome heterogeneity for precision immunotherapy

npj Genomic Medicine(2023)10.1038/s41525-023-00359-8

N/A

0.685DataRank · unranked

21 citations

Razelle Kurzrock, Nicholas Bevins, Kartheeswaran Thangathurai, Suzanna Lee, Sarabjot Pabla +8 more

Comprehensive genomic landscape and precision therapeutic approach in biliary tract cancers

International Journal of Cancer(2020)10.1002/ijc.33230

N/A

0.650DataRank · unranked

75 citations

Razelle Kurzrock, Robert J. Mallory, Paul T. Fanta, Adam M. Burgoyne, Bryan M. Clary +3 more

Expression of TIM3/VISTA checkpoints and the CD68 macrophage-associated marker correlates with anti-PD1/PDL1 resistance: implications of immunogram heterogeneity

OncoImmunology(2020)10.1080/2162402x.2019.1708065

N/A

0.635DataRank · unranked

68 citations

Ryosuke Okamura, Yuichi Kumaki, Sadakatsu Ikeda, Mina Nikanjam, Ramez N. Eskander +9 more

Role of ultraviolet mutational signature versus tumor mutation burden in predicting response to immunotherapy

Molecular Oncology(2020)10.1002/1878-0261.12748

N/A

0.621DataRank · unranked

62 citations

Amélie Boichard, Aaron M. Goodman, Paul Riviere, Huwate Yeerna, Pablo Tamayo +2 more

Circulating Tumor Cells: From the Laboratory to the Cancer Clinic

Cancers(2020)10.3390/cancers12092361

N/A

0.587DataRank · unranked

49 citations

Razelle Kurzrock, Ruchi Agashe

Clinically oriented prediction of patient response to targeted and immunotherapies from the tumor transcriptome

Med(2022)10.1016/j.medj.2022.11.001

N/A

0.564DataRank · unranked

42 citations

Eldad D. Shulman, Efrat Elis, Doreen S. Ben-Zvi, Omer Tirosh, Eden Maimon +26 more

Concomitant MEK and Cyclin Gene Alterations: Implications for Response to Targeted Therapeutics

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-20-3761

N/A

0.561DataRank · unranked

41 citations

Jacob J. Adashek, Justin Shaya, Ryosuke Okamura, Rebecca E. Jimenez, Suzanna Lee +3 more

Nectin-4 expression patterns and therapeutics in oncology

Cancer Letters(2025)10.1016/j.canlet.2025.217681

N/A

0.549DataRank · unranked

20 citations

Judith Pérez‐Granado, Mark Gramling, Bruno Larvol, Razelle Kurzrock, Mina Nikanjam

Establishment of Patient-Derived Succinate Dehydrogenase–Deficient Gastrointestinal Stromal Tumor Models for Predicting Therapeutic Response

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-21-2092

N/A

0.546DataRank · unranked

37 citations

Shruti Bhargava, Avi Kumar, Adam M. Burgoyne, Chih-Min Tang, Hyunho Yoon +17 more

IGF-1R/mTOR Targeted Therapy for Ewing Sarcoma: A Meta-Analysis of Five IGF-1R-Related Trials Matched to Proteomic and Radiologic Predictive Biomarkers

Cancers(2020)10.3390/cancers12071768

N/A

0.542DataRank · unranked

36 citations

Ajaykumar C. Morani, Najat C. Daw, Salah-Eddine Lamhamedi-Cherradi, Vivek Subbiah, Brian A. Menegaz +22 more

Dual anti-CTLA-4 and anti-PD-1 blockade in metaplastic carcinoma of the breast: Dart (SWOG S1609, Cohort 36).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.1073

N/A

0.524DataRank · unranked

32 citations

Megan Othus, Sandip Pravin Patel, Young Kwang Chae, Kathy D. Miller, Rashmi Chugh +8 more

Viewing the immune checkpoint VISTA: landscape and outcomes across cancers

ESMO Open(2024)10.1016/j.esmoop.2024.102942

N/A

0.524DataRank · unranked

32 citations

Razelle Kurzrock, Hirotaka Miyashita, Jacob J. Adashek, Suzanna Lee, Mina Nikanjam +10 more

High prevalence of clonal hematopoiesis‐type genomic abnormalities in cell‐freeDNAin invasive gliomas after treatment

International Journal of Cancer(2021)10.1002/ijc.33481

N/A

0.524DataRank · unranked

32 citations

David Piccioni, Amélie Boichard, Suzanna Lee, Rebecca E. Jimenez, Jason K. Sicklick +3 more

LAG‐3 transcriptomic expression patterns across malignancies: Implications for precision immunotherapeutics

Cancer Medicine(2023)10.1002/cam4.6000

N/A

0.524DataRank · unranked

32 citations

Shumei Kato, Daisuke Nishizaki, Hirotaka Miyashita, Pradip De, Suzanna Lee +7 more

Transcriptomic-Based Microenvironment Classification Reveals Precision Medicine Strategies for Pancreatic Ductal Adenocarcinoma

Gastroenterology(2024)10.1053/j.gastro.2024.01.028

N/A

0.515DataRank · unranked

30 citations

Olga Kudryashova, Andrey Kravets, Samih Z Thalji, Subramaniam Malarkannan, Razelle Kurzrock +21 more

Pan‐cancer analysis of TIM‐3 transcriptomic expression reveals high levels in pancreatic cancer and interpatient heterogeneity

Cancer Medicine(2023)10.1002/cam4.6844

N/A

0.514DataRank · unranked

13 citations

Razelle Kurzrock, Daisuke Nishizaki, Hirotaka Miyashita, Jacob J. Adashek, Suzanna Lee +7 more

If it’s a target, it’s a pan-cancer target: Tissue is not the issue

Cancer Treatment Reviews(2024)10.1016/j.ctrv.2024.102721

N/A

0.510DataRank · unranked

29 citations

Shumei Kato, Jason K. Sicklick, Scott M. Lippman, Razelle Kurzrock, Jacob J. Adashek

A Phase II Basket Trial of Dual Anti–CTLA-4 and Anti–PD-1 Blockade in Rare Tumors (DART SWOG 1609 Cohort 47) in Patients with Gestational Trophoblastic Neoplasia

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-23-2293

N/A

0.505DataRank · unranked

28 citations

Megan Othus, Young Kwang Chae, Michael J. Dennis, Sarah Gordon, David G. Mutch +9 more

Phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors (DART) SWOG S1609: adrenocortical carcinoma cohort

Journal for ImmunoTherapy of Cancer(2024)10.1136/jitc-2024-009074

N/A

0.503DataRank · unranked

12 citations

Megan Othus, Young Kwang Chae, Tridu R. Huynh, Benjamin Tan, Timothy M. Kuzel +9 more

SWOG 1609 cohort 48: anti–CTLA‐4 and anti–PD‐1 for advanced gallbladder cancer

Cancer(2024)10.1002/cncr.35243

N/A

0.496DataRank · unranked

15 citations

Elizabeth Guadarrama, Young Kwang Chae, Michael J. Dennis, Benjamin Powers, Chih‐Yi Liao +9 more

Dataset of phase I and II immunotherapy clinical trials used for a meta-analysis to assess the role of biomarkers in treatment outcomes in diverse cancers

Data in Brief(2023)10.1016/j.dib.2023.109698

Top 40%

0.477DataRank

Top 40%4 citations

Henry Hiep Vo, Peter Müeller, Razelle Kurzrock, Apostolia M. Tsimberidou, Elena Fountzilas

Cancer-Immunity Marker RNA Expression Levels across Gynecologic Cancers: Implications for Immunotherapy

Molecular Cancer Therapeutics(2023)10.1158/1535-7163.mct-23-0270

N/A

0.457DataRank · unranked

9 citations

Shumei Kato, Hirotaka Miyashita, Kartheeswaran Thangathurai, Sarabjot Pabla, Paul DePietro +6 more

Pan-cancer molecular tumor board experience with biomarker-driven precision immunotherapy

npj Precision Oncology(2022)10.1038/s41698-022-00309-0

N/A

0.434DataRank · unranked

17 citations

Shumei Kato, Ki Hwan Kim, Hyo Jeong Lim, Ryosuke Okamura, Ramez N. Eskander +7 more

Immunotherapy in Breast Cancer and the Potential Role of Liquid Biopsy

Frontiers in Oncology(2022)10.3389/fonc.2022.802579

N/A

0.425DataRank · unranked

16 citations

Özge Gümüşay, Razelle Kurzrock, L. J. van ‘t Veer, Hope S. Rugo, Mark Jesus M. Magbanua

Correlation between tumor size change and outcome in a rare cancer immunotherapy basket trial

JNCI Journal of the National Cancer Institute(2024)10.1093/jnci/djae009

Top 44%

0.418DataRank

Top 44%6 citations

Sandip Pravin Patel, Young Kwang Chae, Eliana Dietrich, Howard Streicher, Elad Sharon +2 more

First cycle toxicity and survival in patients with rare cancers treated with checkpoint inhibitors

JNCI Journal of the National Cancer Institute(2024)10.1093/jnci/djae297

Top 47%

0.385DataRank

Top 47%8 citations

Sandip Pravin Patel, Young Kwang Chae, Eliana Dietrich, Howard Streicher, Elad Sharon +2 more

Multi‐omic analysis in carcinoma of unknown primary ( CUP ): therapeutic impact of knowing the unknown

Molecular Oncology(2022)10.1002/1878-0261.13293

N/A

0.385DataRank · unranked

12 citations

Sophia Gumas, Jacob J. Adashek, Ryosuke Okamura, Suzanna Lee, Jason K. Sicklick +2 more

Osteosarcoma with cell-cycle and fibroblast growth factor genomic alterations: case report of Molecular Tumor Board combination strategy resulting in long-term exceptional response

Journal of Hematology & Oncology(2022)10.1186/s13045-022-01344-x

N/A

0.385DataRank · unranked

12 citations

Shumei Kato, Pradip De, Jacob J. Adashek, Jason K. Sicklick, Vivek Subbiah +2 more

Phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) SWOG S1609: the desmoid tumors

Journal for ImmunoTherapy of Cancer(2024)10.1136/jitc-2024-009128

N/A

0.380DataRank · unranked

9 citations

Megan Othus, Sandip Pravin Patel, Benjamin Powers, Chung-Tsen Hsueh, Rangaswamy Govindarajan +11 more

SWOG/NCI Phase II Dual Anti–CTLA-4/PD-1 Blockade in Rare Tumors: Nonepithelial Ovarian Cancer

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-24-0606

N/A

0.373DataRank · unranked

11 citations

Megan Othus, Sandip Pravin Patel, Kelly J. Wilkinson, Emily M. Whitman-Purves, Jayanthi Lea +21 more

Molecular Tumor Board for Unicorns: Outcomes for rare and ultra-rare cancers using an N-of-One personalized treatment strategy

iScience(2024)10.1016/j.isci.2024.110465

N/A

0.360DataRank · unranked

10 citations

Shumei Kato, Jordan S. Lim, Ki Hwan Kim, Hyo Jeong Lim, Ryosuke Okamura +6 more

High indoleamine 2,3-dioxygenase transcript levels predict better outcome after front-line cancer immunotherapy

iScience(2024)10.1016/j.isci.2024.109632

N/A

0.360DataRank · unranked

10 citations

Shumei Kato, Daisuke Nishizaki, Hirotaka Miyashita, Suzanna Lee, Mary Nesline +6 more

ICOS and ICOS ligand: expression patterns and outcomes in oncology patients

Therapeutic Advances in Medical Oncology(2025)10.1177/17588359251330514

N/A

0.343DataRank · unranked

8 citations

Shumei Kato, Daisuke Nishizaki, Donald A. Barkauskas, Sarabjot Pabla, Mary Nesline +4 more

Higher tumor mutational burden and PD-L1 expression correlate with shorter survival in hematologic malignancies

Therapeutic Advances in Medical Oncology(2024)10.1177/17588359241273053

N/A

0.339DataRank · unranked

6 citations

Aaron Trando, Sean D. Thomas, Paul Riviere, Patrick J. Sakowski, Ethan S. Sokol +3 more

Attrition of Patients on a Precision Oncology Trial: Analysis of the I-PREDICT Experience

The Oncologist(2020)10.1002/onco.13532

N/A

0.330DataRank · unranked

8 citations

Jason K. Sicklick, Shumei Kato, Ryosuke Okamura, Vincent A. Miller, Brian Leyland‐Jones +3 more

Dual anti-CTLA-4 and anti-PD-1 blockade in metastatic basal cell carcinoma

npj Precision Oncology(2025)10.1038/s41698-024-00798-1

N/A

0.303DataRank · unranked

5 citations

Eleanor Cano-Linson, Young Kwang Chae, Shiruyeh Schokrpur, Christopher D. Lao, Benjamin Powers +13 more

A Phase II Basket Trial of Dual Anti–CTLA-4 and Anti–PD-1 Blockade in Rare Tumors SWOG S1609: Vulvar Cancers

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-24-1957

N/A

0.292DataRank · unranked

6 citations

Lucy Corthell, Sandip Pravin Patel, Robert P. Edwards, Jennifer Scalici, Hye Sung Kim +10 more

SWOG S2012: Randomized phase II/III trial of first line platinum/etoposide (P/E) with or without atezolizumab (NSC#783608) in patients (pts) with poorly differentiated extrapulmonary small cell neuroendocrine carcinomas (NEC).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.tps4179

N/A

0.269DataRank · unranked

5 citations

Edward Mayerson, E. Gabriela Chiorean, Earle F. Burgess, Elizabeth M. Swisher, Carl M. Gay +9 more

Phase II basket trial of Dual Anti-CTLA-4 and anti-PD-1 blockade in Rare Tumors (DART) SWOG S1609: pancreatic neuroendocrine neoplasm (PNEN) cohort

Journal for ImmunoTherapy of Cancer(2025)10.1136/jitc-2025-011760

N/A

0.245DataRank · unranked

4 citations

Jillian Fisher, Young Kwang Chae, Luisa M. Solis Soto, Anup Kasi, Bhavana Konda +27 more

4‐1BB transcriptomic expression patterns across malignancies: Implications for clinical trials of 4‐1BB agonists

Cancer Communications(2024)10.1002/cac2.12592

N/A

0.241DataRank · unranked

4 citations

Shumei Kato, Daisuke Nishizaki, Hirotaka Miyashita, Suzanna Lee, Mary Nesline +7 more

A phase II basket trial of dual anti‐CTLA‐4 and anti‐PD‐1 blockade in rare tumors (DART) SWOG S1609: durable responses and delayed pseudoprogression in small cell carcinoma of the ovary, hypercalcemic type cohort

Cancer Communications(2025)10.1002/cac2.70020

N/A

0.208DataRank · unranked

3 citations

Megan Othus, Sandip Pravin Patel, Raid Aljumaily, Khine Z. Win, Tanya Pejovic +12 more

Mutant and Wild-Type RAS Cross-talk and Stoichiometric Deficiencies Are Determinants of Sensitivity to Targeted Therapies in KRASG12R Pancreatic Ductal Adenocarcinoma

Cancer Research(2025)10.1158/0008-5472.can-25-0018

N/A

0.208DataRank · unranked

3 citations

G. Aaron Hobbs, Raven Davidson, Daniel Dorbin, J.J. Gómez Herrera, John F. Langenheim +22 more

Cracking the resistance code: The molecular reclassification of cancer and precision therapy strategies

Seminars in Cancer Biology(2025)10.1016/j.semcancer.2025.10.004

N/A

0.208DataRank · unranked

3 citations

Razelle Kurzrock, Mina Nikanjam

Clinically oriented prediction of patient response to targeted and immunotherapies from the tumor transcriptome.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.1553

N/A

0.188DataRank · unranked

2 citations

Gal Dinstag, Eldad D. Shulman, Efrat Elis, Doreen S. Ben-Zvi, Omer Tirosh +15 more

Case series of outcomes in advanced cancer patients with single pathway alterations receiving N-of-One therapies

npj Precision Oncology(2022)10.1038/s41698-022-00259-7

Top 71%

0.123DataRank

Top 71%1 citations

Razelle Kurzrock, Suzanna Lee, Ryosuke Okamura, Hyo Jeong Lim, Ki Hwan Kim +3 more

Pan-cancer B- and T-cell transcriptome analysis of CXCL13 as a predictive marker for immune checkpoint inhibitor response.

Journal of Clinical Oncology(2024)10.1200/jco.2024.42.16_suppl.2626

N/A

0.104DataRank · unranked

1 citations

Shumei Kato, Daisuke Nishizaki, Hirotaka Miyashita, Suzanna Lee, Mary Nesline +5 more

Targeting G1-S phase cell-cycle alterations with CDK4/6 inhibitor-based genomically matched personalized therapy approach.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.3623

N/A

0.104DataRank · unranked

1 citations

Shumei Kato, Ryosuke Okamura, Noor Khalid, Suzanna Lee, Van Thomas Nguyen +3 more

Efficacy and CNS Toxicity of Nivolumab and Ipilimumab in Rare Cancer Brain Metastases: A Multicenter Basket Trial Analysis (NCI/SWOG S1609)

Clinical Cancer Research(2025)10.1158/1078-0432.ccr-25-2900

N/A

0.104DataRank · unranked

1 citations

S Solomon, Sandip Pravin Patel, Zouina Sarfraz, Megan Othus, Young Kwang Chae +2 more

Phase II trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors SWOG/NCI experience: invasive mucinous or non-mucinous lepidic adenocarcinoma of the lung (formerly bronchioloalveolar carcinoma)

Therapeutic Advances in Medical Oncology(2024)10.1177/17588359241293401

N/A

0.104DataRank · unranked

1 citations

Megan Othus, Sandip Pravin Patel, David E. Gerber, Tawee Tanvetyanon, Hye Sung Kim +10 more

Autoimmune HLA Alleles and Neoepitope Presentation Predict Post-Allogenic Transplant Relapse

Journal of Immunotherapy and Precision Oncology(2023)10.36401/jipo-22-19

N/A

0.104DataRank · unranked

1 citations

Aaron M. Goodman, Zachary Rane, James V. Talwar, Garrett M. Frampton, Gerald P. Morris +5 more

Whole exome precision oncology targeting synthetic lethal vulnerabilities across the tumor transcriptome

bioRxiv (Cold Spring Harbor Laboratory)(2020)10.1101/2020.02.16.951699

N/A

0.104DataRank · unranked

1 citations

Nishanth Ulhas Nair, Lesley M. Chapman, Sanju Sinha, Kun Wang, Houngui Cha +10 more

Evaluation of change in RECIST tumor size and survival in patients with rare cancers treated with checkpoint inhibitor therapy (SWOG S1609).

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.2504

N/A

0.104DataRank · unranked

1 citations

Sandip Pravin Patel, Young Kwang Chae, Eliana Dietrich, Howard Streicher, Elad Sharon +2 more

Data from A Multicenter Phase II Trial of Ipilimumab and Nivolumab in Unresectable or Metastatic Metaplastic Breast Cancer: Cohort 36 of Dual Anti–CTLA-4 and Anti–PD-1 Blockade in Rare Tumors (DART, SWOG S1609)

10.1158/1078-0432.c.6530837.v1

N/A

0DataRank · unranked

0 citations

Megan Othus, Sandip Pravin Patel, Kathy D. Miller, Rashmi Chugh, Scott M. Schuetze +23 more

BAP1: Not just a BRCA1-associated protein

Cancer Treatment Reviews(2020)10.1016/j.ctrv.2020.102091

N/A

0DataRank · unranked

204 citations

Razelle Kurzrock, Bryan H. Louie

Relationship between tumor mutational burden and maximum standardized uptake value in 2-[18F]FDG PET (positron emission tomography) scan in cancer patients

EJNMMI Research(2020)10.1186/s13550-020-00732-z

N/A

0DataRank · unranked

14 citations

Donald A. Barkauskas, Matthew Zabel, Aaron M. Goodman, Garrett M. Frampton, Mina Nikanjam +3 more

Precision oncology: the intention-to-treat analysis fallacy

European Journal of Cancer(2020)10.1016/j.ejca.2020.04.002

N/A

0DataRank · unranked

8 citations

Shumei Kato, Ryosuke Okamura, Razelle Kurzrock, Jason K. Sicklick

Prognostic Utility of Pre- and Postoperative Circulating Tumor DNA Liquid Biopsies in Patients with Peritoneal Metastases

Annals of Surgical Oncology(2020)10.1245/s10434-020-08331-x

N/A

0DataRank · unranked

23 citations

Paul Riviere, Richard B. Lanman, Kaitlyn J. Kelly, Jula Veerapong, Andrew M. Lowy +2 more

Signed in Blood: Circulating Tumor DNA in Cancer Diagnosis, Treatment and Screening

Cancers(2021)10.3390/cancers13143600

N/A

0DataRank · unranked

93 citations

Filip Jankú, Razelle Kurzrock, Jacob J. Adashek

A phase 2, open-label, multicenter study of the long-term safety of siltuximab (an anti-interleukin-6 monoclonal antibody) in patients with multicentric Castleman disease

UNC Libraries(2020)10.17615/tfn8-cp59

N/A

0DataRank · unranked

0 citations

Ming Qi, Peter M. Voorhees, Frits van Rhee, Razelle Kurzrock, Luis Fayad +5 more

Synthetic lethality-mediated precision oncology via the tumor transcriptome

Cell(2021)10.1016/j.cell.2021.03.030

N/A

0DataRank · unranked

159 citations

Nishanth Ulhas Nair, Gal Dinstag, Lesley M. Chapman, Youngmin Chung, Kun Wang +18 more

Wedding of Molecular Alterations and Immune Checkpoint Blockade: Genomics as a Matchmaker

JNCI Journal of the National Cancer Institute(2021)10.1093/jnci/djab067

N/A

0DataRank · unranked

48 citations

Razelle Kurzrock, Henry Hiep Vo, Apostolia M. Tsimberidou, Elena Fountzilas

Assessing CAR T-Cell Therapy Response Using Genome-Wide Sequencing of Cell-Free DNA in Patients With B-Cell Lymphomas

Transplantation and Cellular Therapy(2021)10.1016/j.jtct.2021.10.007

N/A

0DataRank · unranked

25 citations

Kimberly A. Holden, Ah‐Reum Jeong, Lisa Kim, Kerry Fitzgerald, Eyad Almasri +11 more

BRAF V600E/V600K Mutations versus Nonstandard Alterations: Prognostic Implications and Therapeutic Outcomes

Molecular Cancer Therapeutics(2021)10.1158/1535-7163.mct-20-0861

N/A

0DataRank · unranked

14 citations

Jose Tinajero, Donald A. Barkauskas, Razelle Kurzrock, Mina Nikanjam

KRAS-Mutated, Estrogen Receptor-Positive Low-Grade Serous Ovarian Cancer: Unraveling an Exceptional Response Mystery

The Oncologist(2021)10.1002/onco.13702

N/A

0DataRank · unranked

14 citations

Thomas McFall, Kenta Takahashi, Kasey Bamel, Sadakatsu Ikeda, Ramez N. Eskander +5 more

Balancing clinical evidence in the context of a pandemic

Nature Biotechnology(2021)10.1038/s41587-021-00834-6

N/A

0DataRank · unranked

11 citations

Razelle Kurzrock, Jacob J. Adashek

Novel somatic alterations in unicentric and idiopathic multicentric Castleman disease

European Journal Of Haematology(2021)10.1111/ejh.13702

N/A

0DataRank · unranked

11 citations

Ah‐Reum Jeong, Alexis Phillips, Huan‐You Wang, Ethan Sokol, Philip R Cohen +4 more

Therapeutic implications of cancer gene amplifications without mRNA overexpression: silence may not be golden

Journal of Hematology & Oncology(2021)10.1186/s13045-021-01211-1

N/A

0DataRank · unranked

7 citations

Scott M. Lippman, Razelle Kurzrock, Amélie Boichard

Unravelling the underpinnings of hyperprogression and immunotherapy: back to the bench

Oncotarget(2021)10.18632/oncotarget.28098

N/A

0DataRank · unranked

0 citations

Razelle Kurzrock, Vivek Subbiah

JAK: Not Just Another Kinase

Molecular Cancer Therapeutics(2022)10.1158/1535-7163.mct-22-0323

N/A

0DataRank · unranked

132 citations

Scott M. Lippman, Razelle Kurzrock, Ruchi Agashe

Variable Mutation Expression in Human Cancers: A “Hide-and-Seek” Mechanism Linked to Differential MHC-I Presentation Dynamics

Molecular Cancer Therapeutics(2022)10.1158/1535-7163.mct-21-0831

N/A

0DataRank · unranked

0 citations

Razelle Kurzrock, Amélie Boichard

1469 A phase II basket trial of dual anti–CTLA-4 and anti–PD-1 blockade in rare tumors (DART SWOG 1609 Cohort 47) in patients with gestational trophoblastic disease

(2022)10.1136/jitc-2022-sitc2022.1469

N/A

0DataRank · unranked

0 citations

Megan Othus, Young Kwang Chae, Michael J. Dennis, Sarah Gordon, David G. Mutch +7 more

Biomarkers and Outcomes in Diverse Cancers: Meta-Analysis of Early Phase Immuno-Oncology Trials

Research Square(2022)10.21203/rs.3.rs-2386222/v1

N/A

0DataRank · unranked

0 citations

Henry Hiep Vo, Peter Müeller, Razelle Kurzrock, Apostolia M. Tsimberidou, Elena Fountzilas

Universal Germline and Tumor Genomic Testing Needed to Win the War Against Cancer: Genomics Is the Diagnosis

Journal of Clinical Oncology(2023)10.1200/jco.22.02833

N/A

0DataRank · unranked

62 citations

Razelle Kurzrock, Vivek Subbiah

Successful treatment of non-Langerhans cell histiocytosis with the MEK inhibitor trametinib: a multicenter analysis

Blood Advances(2023)10.1182/bloodadvances.2022009013

N/A

0DataRank · unranked

47 citations

Razelle Kurzrock, Gaurav Goyal, Aaron M. Goodman, Harsh Patel, Gordon Ruan +8 more

Evolution of Precision Oncology, Personalized Medicine, and Molecular Tumor Boards

Surgical Oncology Clinics of North America(2023)10.1016/j.soc.2023.12.004

N/A

0DataRank · unranked

14 citations

Shumei Kato, Razelle Kurzrock, Yu Fujiwara

Correlation between biomarkers and treatment outcomes in diverse cancers: a systematic review and meta-analysis of phase I and II immunotherapy clinical trials

European Journal of Cancer(2023)10.1016/j.ejca.2023.05.015

N/A

0DataRank · unranked

19 citations

Henry Hiep Vo, Peter Müeller, Razelle Kurzrock, Apostolia M. Tsimberidou, Elena Fountzilas

At the right dose: personalised (N-of-1) dosing for precision oncology

European Journal of Cancer(2023)10.1016/j.ejca.2023.113359

N/A

0DataRank · unranked

12 citations

Shumei Kato, Jason K. Sicklick, Razelle Kurzrock, Mina Nikanjam

Increased KRAS G12C Prevalence, High Tumor Mutational Burden, and Specific Mutational Signatures Are Associated With MUTYH Mutations: A Pan-Cancer Analysis

The Oncologist(2023)10.1093/oncolo/oyad230

N/A

0DataRank · unranked

5 citations

Smruthy Sivakumar, Tim Pham, Zoë Fleischmann, Anu R I, Ethan Sokol +2 more

Cancer immunity marker RNA expression levels across gynecologic cancers: Implications for immunotherapy

Research Square(2023)10.21203/rs.3.rs-2551645/v1

N/A

0DataRank · unranked

2 citations

Shumei Kato, Hirotaka Miyashita, Kartheeswaran Thangathurai, Sarabjot Pabla, Paul DePietro +6 more

A phase II basket trial of dual anti–CTLA-4 and anti–PD-1 blockade in rare tumors (DART) SWOG S1609: The vulvar cancers.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.5517

N/A

0DataRank · unranked

4 citations

Megan Othus, Sandip Pravin Patel, Robert P. Edwards, Jennifer Scalici, Liam Il‐Young Chung +8 more

Tumor-agnostic baskets to N-of-1 platform trials and real-world data: Transforming precision oncology clinical trial design

Cancer Treatment Reviews(2024)10.1016/j.ctrv.2024.102703

N/A

0DataRank · unranked

22 citations

Apostolia M. Tsimberidou, Henry Hiep Vo, Razelle Kurzrock, Elena Fountzilas

Data from A Multicenter Phase II Trial of Ipilimumab and Nivolumab in Unresectable or Metastatic Metaplastic Breast Cancer: Cohort 36 of Dual Anti–CTLA-4 and Anti–PD-1 Blockade in Rare Tumors (DART, SWOG S1609)

(2023)10.1158/1078-0432.c.6530837

N/A

0DataRank · unranked

0 citations

Megan Othus, Sandip Pravin Patel, Kathy D. Miller, Rashmi Chugh, Scott M. Schuetze +23 more

Data from Phase I Oncology Studies: Evidence That in the Era of Targeted Therapies Patients on Lower Doses Do Not Fare Worse

(2023)10.1158/1078-0432.c.6519332.v1

N/A

0DataRank · unranked

0 citations

J. Jack Lee, David S. Hong, Maurie Markman, Jing Gong, Aung Naing +3 more

Supplementary Data from Establishment of Patient-Derived Succinate Dehydrogenase–Deficient Gastrointestinal Stromal Tumor Models for Predicting Therapeutic Response

INDIGO (University of Illinois at Chicago)(2023)10.1158/1078-0432.22482656.v1

Top 100%

0DataRank

Top 100%0 citations

Shruti Bhargava, Avi Kumar, Adam M. Burgoyne, Chih‐Min Tang, Hyunho Yoon +17 more

Data from Phase I Oncology Studies: Evidence That in the Era of Targeted Therapies Patients on Lower Doses Do Not Fare Worse

(2023)10.1158/1078-0432.c.6519332

N/A

0DataRank · unranked

0 citations

J. Jack Lee, David S. Hong, Maurie Markman, Jing Gong, Aung Naing +3 more

Data from Concomitant MEK and Cyclin Gene Alterations: Implications for Response to Targeted Therapeutics

(2023)10.1158/1078-0432.c.6529977

N/A

0DataRank · unranked

0 citations

Jacob J. Adashek, Justin Shaya, Ryosuke Okamura, Rebecca E. Jimenez, Suzanna Lee +3 more

Data from Molecular imaging of Bcr-Abl phosphokinase in a xenograft model

(2023)10.1158/1535-7163.c.6531533

N/A

0DataRank · unranked

0 citations

David J. Yang, Laura S. Angelo, Saady Kohanim, Razelle Kurzrock, Ji Yuan Wu

Data from Establishment of Patient-Derived Succinate Dehydrogenase–Deficient Gastrointestinal Stromal Tumor Models for Predicting Therapeutic Response

(2023)10.1158/1078-0432.c.6530975.v1

N/A

0DataRank · unranked

0 citations

Shruti Bhargava, Avi Kumar, Adam M. Burgoyne, Chih‐Min Tang, Hyunho Yoon +17 more

Outcome differences by sex in oncology clinical trials.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.e18808

Top 100%

0DataRank

Top 100%0 citations

Alejandro A. Schäffer, Padma Sheila Rajagopal, Razelle Kurzrock, Fiorella Schischlik, Ashwin V. Kammula

A phase II basket trial of dual anti–CTLA-4 and anti–PD-1 blockade in rare tumors (DART SWOG 1609) in patients with refractory gallbladder cancer (cohort 48).

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.e16330

N/A

0DataRank · unranked

0 citations

Elizabeth Guadarrama, Young Kwang Chae, Chih‐Yi Liao, Anup Kasi, Grace R. Tarabay +12 more

Pan-cancer analysis of IDO1 transcriptome expression and its impact on outcome in patients treated with immune checkpoint inhibitors.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.2614

N/A

0DataRank · unranked

0 citations

Shumei Kato, Daisuke Nishizaki, Hirotaka Miyashita, Suzanna Lee, Mary Nesline +6 more

A phase II basket trial of dual anti–CTLA-4 and anti–PD-1 blockade in rare tumors (DART) SWOG S1609: The desmoid tumors (cohort 27).

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.11516

N/A

0DataRank · unranked

0 citations

Megan Othus, Sandip Pravin Patel, Benjamin Powers, Chung-Tsen Hsueh, Rangaswamy Govindarajan +10 more

Precision oncology across the ages: Impact on children, adolescents, and young adults

Cancer Cell(2024)10.1016/j.ccell.2024.08.010

N/A

0DataRank · unranked

10 citations

Razelle Kurzrock, Vivek Subbiah

Reverse repurposing: Potential utility of cancer drugs in nonmalignant illnesses

Med(2024)10.1016/j.medj.2024.04.008

N/A

0DataRank · unranked

7 citations

Kaitlyn Wells, Shumei Kato, Jacob J. Adashek, Shanna Block, Razelle Kurzrock +1 more

An Annual Symposium on Disparities in Milwaukee, WI, with a 2023 Focus on Older Adults with Cancer

Current Oncology Reports(2024)10.1007/s11912-024-01525-6

N/A

0DataRank · unranked

1 citations

June M. McKoy, Grant R. Williams, Nikesha Gilmore, Christina A. Minami, Kathryn Bylow +8 more

Critical insights into the evolving drug‐approval process in China

Cancer(2024)10.1002/cncr.35186

N/A

0DataRank · unranked

0 citations

Razelle Kurzrock, Mina Nikanjam

Toll-like receptor 3: a double-edged sword

Biomarker Research(2025)10.1186/s40364-025-00739-5

N/A

0DataRank · unranked

33 citations

Daisuke Nishizaki, Jacob J. Adashek, Shumei Kato, Razelle Kurzrock, Marvin L Hsieh

Tumour-agnostic kinase inhibitors

Nature Reviews Drug Discovery(2025)10.1038/s41573-025-01147-y

N/A

0DataRank · unranked

14 citations

Mina Nikanjam, Razelle Kurzrock, Jacob J. Adashek

Novel clinical trial designs emerging from the molecular reclassification of cancer

CA A Cancer Journal for Clinicians(2025)10.3322/caac.21880

N/A

0DataRank · unranked

11 citations

Shumei Kato, Teresa Allen, Jason K. Sicklick, Razelle Kurzrock, Mina Nikanjam

OncoAID: an open access targeted anti-cancer drugs database

Frontiers in Pharmacology(2025)10.3389/fphar.2025.1588191

N/A

0DataRank · unranked

3 citations

Shai Magidi, Catherine Bresson, Fanny Wunder, Razelle Kurzrock, Wafik S. El‐Deiry +3 more

Response to: The pathway alteration load is a pan-cancer determinant of outcome of targeted therapies: results from the Drug Rediscovery Protocol (DRUP)

ESMO Open(2025)10.1016/j.esmoop.2025.104516

N/A

0DataRank · unranked

0 citations

Razelle Kurzrock, Damian Rieke

Tumor mutational burden, PD-1, negative Wnt/β-catenin regulators, and positive MHC class II antigen presentation regulators as predictors of longer survival after immune checkpoint inhibitors across cancers: A comprehensive analysis of 400 immunity biomarkers.

Journal of Clinical Oncology(2025)10.1200/jco.2025.43.16_suppl.2625

N/A

0DataRank · unranked

0 citations

Shumei Kato, Daisuke Nishizaki, Hirotaka Miyashita, Suzanna Lee, Mary Nesline +6 more

Natural killer cell transcriptomic expression and prediction of survival after immune checkpoint blockade across cancers.

Journal of Clinical Oncology(2025)10.1200/jco.2025.43.16_suppl.2518

N/A

0DataRank · unranked

0 citations

Daisuke Nishizaki, Suzanna Lee, Taylor J. Jensen, Shumei Kato, Paul DePietro +3 more

Incidence of mucositis in patients treated with mTOR inhibitor-based regimens and correlation to treatment response.

Journal of Clinical Oncology(2013)10.1200/jco.2013.31.15_suppl.e13575

N/A

0DataRank · unranked

0 citations

David S. Hong, Siqing Fu, Sarina Anne Piha-Paul, Lacey McQuinn, Gerald Steven Falchook +11 more

Razelle Kurzrock

Indexed papers

Top data-sharing exemplar

Papers